Related Experiment Video
Updated: Sep 15, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review
Qing-Yun Wu1,2, Li-Rong Mo1, Jing Nan3
1Department of Cardiology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Insights
The hemoglobin glycation index (HGI) offers better long-term glycemic control assessment than HbA1c. Elevated HGI is linked to cardiometabolic diseases, aiding clinical risk prediction.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Medicine
- Clinical Biochemistry
Background:
- Hemoglobin glycation index (HGI) is a biomarker for long-term glycemic control.
- HGI provides a more comprehensive assessment than glycated hemoglobin (HbA1c).
- Elevated HGI correlates with cardiometabolic diseases (CMDs).
Purpose of the Study:
- To review the clinical utility of HGI in various cardiometabolic conditions.
- To provide clinicians with an enhanced framework for disease stratification and management.
- To explore HGI's role in coronary artery disease, hypertension, heart failure, diabetes mellitus, serum uric acid levels, and nonalcoholic fatty liver disease.
Main Methods:
- Systematic review of current evidence on HGI.
- Synthesis of studies evaluating HGI in relation to CMDs.
- Analysis of HGI's prognostic and therapeutic implications.
Main Results:
- HGI is a significant predictor of cardiometabolic disease incidence.
- Evidence supports HGI's utility across diverse conditions including CAD, HF, DM, and NAFLD.
- HGI aids in precise disease stratification and therapeutic optimization.
Conclusions:
- HGI is a valuable biomarker for assessing long-term glycemic control and CMD risk.
- Integrating HGI into clinical practice can enhance patient management and prognosis.
- Further research into HGI's applications is warranted.
Abstract:
The hemoglobin glycation index (HGI) has emerged as a pivotal biomarker for evaluating long-term glycemic control, offering a more comprehensive assessment compared with conventional glycated hemoglobin (HbA1c) measurements. Elevated HGI levels are significantly correlated with the incidence of cardiometabolic diseases (CMDs). This review synthesizes current evidence on the clinical utility of the HGI across coronary artery disease (CAD), hypertension, heart failure (HF), diabetes mellitus (DM), serum uric acid (SUA) levels, and nonalcoholic fatty liver disease (NAFLD), thereby providing clinicians with an enhanced framework for precise disease stratification, therapeutic optimization, and prognostic prediction.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Related Concept Videos
Coronary Artery Disease I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes: Symptoms, Diagnosis, and Complications
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Proteoglycans